Omiganan (previously known as MBI-226), is a synthetic, linear, 12 amino acid, cationic peptide analog of indolicidin, being developed as a topical gel for prevention of catheter-associated infections. In September 2000, a phase III trial of omiganan for the potential prevention of catheter-related bloodstream infections was initiated. In July 2018 was completed phase III clinical trial where was evaluated the long-term safety of once-daily application of omiganan topical gel in subjects with severe papulopustular rosacea. In addition, omiganan successfully completed phase II clinical trials where was determined its safety/tolerability in patients with mild to moderate atopic dermatitis and in human subjects with facial acne vulgaris. Besides, omiganan is ongoing phase II to explore the efficacy and pharmacodynamic effects of its topical gel in facial seborrheic dermatitis.

Selepressin (FE 202158) was designed as a selective and short-acting vasopressin type 1a receptor (V(1a)R) agonist. This drug was developed for the treatment of vasodilatory hypotension in shock. Selepressin successfully completed phase IIa clinical trial, where was found that in septic shock patients, selepressin 2.5 ng/kg/minute was able to rapidly replace norepinephrine, improve fluid balance and shorten the time of mechanical ventilation.

Murepavadin is the first in class of the outer membrane protein-targeting antibiotics (OMPTA) and a pathogen-specific peptidomimetic antibacterial with a novel, nonlytic mechanism of action targeting Pseudomonas aeruginosa. Murepavadin is being developed by Polyphor Ltd for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia. In preclinical studies, Murepavadin was highly effective against Pseudomonas aeruginosa, without evidence of generating resistance. Murepavadin has been evaluated in 8 clinical studies. Murepavadin penetrates into lung tissue and showed encouraging results in a Phase II study when given on top of standard of care in patients with Ventilator-Associated Bacterial Pneumonia. The phase III clinical trial was initiated in 2018 to assess the efficacy, safety, and tolerability of Murepavadin in adult subjects with ventilator-associated bacterial pneumonia. But in May 2019, Polyphor Ltd. suspended the global phase III trial for safety data review.

Delparantag is a novel, salicylamide-derived, small molecule. Delparantag is heptagonist. It acts as universal anticoagulation-reversing agent. Delparantag neutralized the antithrombotic, anticoagulant, and bleeding effects of heparins as effectively as protamine sulfate and may be slightly more efficacious against low-molecular-weight heparins (LMWHs). This agent was designed to restore coagulation by specifically binding to the pentasaccharide and disrupting unfractionated heparin and LMWH interaction with antithrombin. Delparantag has been shown to completely reverse the anticoagulant effects of heparin and normalize blood-clotting time in six human subjects in less than 10 minutes in a phase IB clinical trial. In clinical trial studies, safety was ascertained by blood pressure measurements and efficacy was determined by measuring blood clotting time (aPTT, Activated Partial Thromboplastin Time, or ACT, Activated Coagulation Time). Plasma half-life elimination of delparantag is between 3 and 5 min. Development was recently paused due to hypotension noted in the studies although this may be avoided with longer administration times and will require further investigation.

Teprotide, a nonapeptide isolated from the venom of a Brazilian pit viper, Bothrops jararaca, was the first angiotensin converting enzyme (ACE) inhibitor to be discovered and tested. It was found to be an effective, non-toxic antihypertensive agent as well as an afterload-reducing agent for patients with congestive heart failure (CHF). The primary activity of teprotide resulted from blockade of the angiotensin I converting enzyme--the pivotal step in the renin-angiotensin-aldosterone system (RAAS), and consequent reductions in angiotensin II levels. There was limited clinical testing for teprotide because of: its scarcity; the need for parenteral administration; and the subsequent discovery and synthesis of captopril, the first orally active angiotensin converting enzyme inhibitor.

Elpamotide is an anti-angiogenic cancer vaccine. It is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) (RFVPDGNRI) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. OncoTherapy Science was developing elpamotide for the treatment of solid tumors.

alpha-MELANOTROPIN (also known as an alpha-melanocyte-stimulating hormone or alpha MSH) is an endogenous melanocortin 1-receptor agonist, which exclusively expressed in cells of the melanocytic lineage. alpha-MELANOTROPIN possesses anti-inflammatory properties and antagonizes proinflammatory mediators, including TNF-alpha, IL-6 and NO, and induces anti-inflammatory cytokine IL-10. alpha-MELANOTROPIN was studied in phase I clinical trial in patients with acute renal failure. In addition, this compound was assigned of orphan designation for the treatment of chronic beryllium disease.

Edratide (hCDR1 or TV-4710) is a peptide based on the sequences of the complementarity determining region (CDR) 1 of monoclonal anti-DNA antibody. The capacity of the peptide to bind to major histocompatibility complex class II molecules correlated with the proliferative responses. Edratide is being developed for the treatment of SLE (Systemic Lupus Erythematosus). Edratide ameliorates the SLE-related autoimmune process by specific upstream immunomodulation through the generation of regulatory T cells.